According to the Zhitong Finance App, Okanvision Bio-B (01477) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 424 million yuan, an increase of 44.1% year on year; adjusted net loss of 57.523 million yuan, a year-on-year decrease of 46.74%; and a loss of 0.12 yuan per share.

According to the announcement, the sharp increase in revenue was mainly due to a significant increase in revenue generated from sales of ophthalmic products (including Eusciying®, Colida®, Alaipin®, and products acquired and authorized by Alcon under the Alcon transaction); and a significant increase in royalties revenue based on sales, mainly driven by the successful commercialization of Boyoujing®.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.